Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Premier Biomedical Inc (BIEI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9444
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Premier Biomedical Inc (Premier Biomedical) is a drug development company that develops medications for debilitating and fatal illnesses. The company offers Feldetrex, a drug candidate used for the treatment of multiple sclerosis, fibromyalgia, blood sepsis and viremia, and cancer. It develops sequential-dialysis technique method that utilizes designer antibodies to physically remove the toxin-producing bacteria out of the blood. Premier Biomedical also provides medications for the treatment of amyotrophic lateral sclerosis, traumatic brain injury, clinical depression, Alzheimer’s disease, atherosclerosis, and others. The company develops its technologies through laboratory, hospital, and clinical trials. Premier Biomedical is headquartered in Mercer, Pennsylvania, the US.

Premier Biomedical Inc (BIEI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Premier Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Premier Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 11
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Premier Biomedical Acquires Rights To Potential Therapy For Retinitis Pigmentosa 14
Partnerships 15
Premier Biomedical and Advanced Technologies Solutions Form Joint Venture 15
Premier Biomedical and Auramedi Farmaceutica to Form Joint Venture 16
Premier Biomedical Enters Into R&D Agreement With William Beaumont Army Medical Center 17
Premier Biomedical Enters into Agreement with University of Texas at El Paso 18
Licensing Agreements 19
Premier Biomedical Amends its Licensing Agreement with University of Texas at El Paso 19
Equity Offering 20
Premier Biomedical Files Registration Statement for Public Offering of Shares for up to USD0.8 Million 20
Premier Biomedical Files Registration Statement for Public Offering of Shares for up to USD1.05 Million 21
Premier Biomedical Raises USD0.2 Million in Second Tranche of Private Placement of Shares and Warrants 22
Premier Biomedical to Raise Funds through Public Offering of Shares 23
Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants 24
Premier Biomedical Withdraws Public Offering of Shares 25
Premier Biomedical Raises USD0.2 Million in Public Offering of Shares 26
Premier Biomedical Withdraws Public Offering of Shares 27
Premier Biomedical Completes Private Placement Of Shares For US$5 Million 28
Premier Biomedical Completes Private Placement Of Shares For US$0.07 Million 29
Premier Biomedical Completes Private Placement Of Shares For US$0.15 Million 30
Premier Biomedical Completes Second Tranche Of Private Placement Of Units For US$0.01 Million 31
Debt Offering 32
Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016 32
Premier Biomedical Raises USD0.1 Million in Private Placement of 10% Notes Due 2017 33
Premier Biomedical Raises USD0.1 million in Fifth and Final Tranche of Private Placement of 10% Notes Due 2016 34
Premier Biomedical Raises Funds in Fourth Tranche of Private Placement of 10% Notes Due 2016 35
Premier Biomedical Raises USD0.1 Million in Second Tranche of Private Placement of 10% Notes Due 2016 36
Premier Biomedical Raises USD1.6 Million in Private Placement of Notes 37
Premier Biomedical Raises USD0.2 Million in First Tranche of Private Placement of 10% Notes Due 2016 38
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 39
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 40
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 41
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 42
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 43
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 44
Premier Biomedical Raises Funds through Private Placement of 10% Notes Due 2015 45
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2014 46
Premier Biomedical Inc – Key Competitors 47
Premier Biomedical Inc – Key Employees 48
Premier Biomedical Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Joint Venture 49
Recent Developments 50
Strategy And Business Planning 50
Aug 21, 2018: Premier Biomedical creates four centers of technological expertise 50
Corporate Communications 51
Jul 30, 2018: Premier Biomedical uplifted to OTCQB 51
Product News 52
Jul 10, 2017: Premier Biomedical Introduces Improved Topical Skin Products 52
Jan 23, 2018: Premier Biomedical Launches Hemp Oil Based Topical Pain Relief Ointment 53
Other Significant Developments 54
Jul 10, 2018: Premier Biomedical CEO Update Letter — July, 2018 54
Feb 28, 2018: Premier Biomedical Searching For Development Partner To Advance Patent Pending Technology 56
Jul 13, 2017: Premier Biomedical Integrates CBD-Based Pain Relief Products Business; Expands Current and New Product Offerings 57
Feb 15, 2017: Multi-Pronged Product Distribution Agreements Announced by Premier Biomedical Pain Management Solutions for Their Superior Pain Relief Products 58
Jan 18, 2017: Premier Biomedical Pain Management Solutions Announces Product Distribution Agreement of Their Superior Pain Relief Products 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Premier Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Premier Biomedical Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Premier Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 11
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Premier Biomedical Acquires Rights To Potential Therapy For Retinitis Pigmentosa 14
Premier Biomedical and Advanced Technologies Solutions Form Joint Venture 15
Premier Biomedical and Auramedi Farmaceutica to Form Joint Venture 16
Premier Biomedical Enters Into R&D Agreement With William Beaumont Army Medical Center 17
Premier Biomedical Enters into Agreement with University of Texas at El Paso 18
Premier Biomedical Amends its Licensing Agreement with University of Texas at El Paso 19
Premier Biomedical Files Registration Statement for Public Offering of Shares for up to USD0.8 Million 20
Premier Biomedical Files Registration Statement for Public Offering of Shares for up to USD1.05 Million 21
Premier Biomedical Raises USD0.2 Million in Second Tranche of Private Placement of Shares and Warrants 22
Premier Biomedical to Raise Funds through Public Offering of Shares 23
Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants 24
Premier Biomedical Withdraws Public Offering of Shares 25
Premier Biomedical Raises USD0.2 Million in Public Offering of Shares 26
Premier Biomedical Withdraws Public Offering of Shares 27
Premier Biomedical Completes Private Placement Of Shares For US$5 Million 28
Premier Biomedical Completes Private Placement Of Shares For US$0.07 Million 29
Premier Biomedical Completes Private Placement Of Shares For US$0.15 Million 30
Premier Biomedical Completes Second Tranche Of Private Placement Of Units For US$0.01 Million 31
Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016 32
Premier Biomedical Raises USD0.1 Million in Private Placement of 10% Notes Due 2017 33
Premier Biomedical Raises USD0.1 million in Fifth and Final Tranche of Private Placement of 10% Notes Due 2016 34
Premier Biomedical Raises Funds in Fourth Tranche of Private Placement of 10% Notes Due 2016 35
Premier Biomedical Raises USD0.1 Million in Second Tranche of Private Placement of 10% Notes Due 2016 36
Premier Biomedical Raises USD1.6 Million in Private Placement of Notes 37
Premier Biomedical Raises USD0.2 Million in First Tranche of Private Placement of 10% Notes Due 2016 38
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 39
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 40
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 41
Premier Biomedical Raises Funds through Private Placement of 12% Notes Due 2016 42
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 43
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2016 44
Premier Biomedical Raises Funds through Private Placement of 10% Notes Due 2015 45
Premier Biomedical Raises Funds through Private Placement of 8% Notes Due 2014 46
Premier Biomedical Inc, Key Competitors 47
Premier Biomedical Inc, Key Employees 48
Premier Biomedical Inc, Joint Venture 49

List of Figures
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Premier Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Premier Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Premier Biomedical Inc (BIEI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bridgford Foods Corporation:企業の戦略・SWOT・財務情報
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • London Stock Exchange Group Plc:戦略・SWOT・企業財務分析
    London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report Summary London Stock Exchange Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Pt Bumi Resources Tbk:企業の戦略・SWOT・財務分析
    Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bumi Resources Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fabric Genomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fabric Genomics Inc (Fabric), formerly Omicia Inc, is a healthcare solutions provider that offers genome interpretation solutions. The company offers Opal, a cloud-based informatics platform that helps to analyze and interpret genomes by prioritizing disease-causing variants and genes. Fabri …
  • Herman Miller Inc (MLHR):企業の財務・戦略的SWOT分析
    Herman Miller Inc (MLHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Novavax Inc (NVAX):製薬・医療:M&Aディール及び事業提携情報
    Summary Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccine …
  • Aerovironment Inc:企業の戦略・SWOT・財務分析
    Aerovironment Inc - Strategy, SWOT and Corporate Finance Report Summary Aerovironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Asatsu-DK Inc.:企業の戦略的SWOT分析
    Asatsu-DK Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • AVI Ltd:企業の戦略・SWOT・財務分析
    AVI Ltd - Strategy, SWOT and Corporate Finance Report Summary AVI Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary NovaDigm Therapeutics Inc (NovaDigm) is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company’s products include NDV-3 vaccines, ALS3 vaccines, vaccine clinical supplies, bacterial and fungal vaccine antigens, vaginal …
  • Iron Mountain Incorporated:企業のM&A・事業提携・投資動向
    Iron Mountain Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iron Mountain Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Sunland Group Ltd:企業の戦略・SWOT・財務情報
    Sunland Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Sunland Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SPAR Osterreichische Warenhandels AG:企業の戦略的SWOT分析
    SPAR Osterreichische Warenhandels AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Voith GmbH & Co KGaA:企業の戦略的SWOT分析
    Voith GmbH & Co KGaA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • VisionCare Inc-医療機器分野:企業M&A・提携分析
    Summary VisionCare Inc (VisionCare) is a medical device company that researches, develops, manufactures, and markets proprietary implantable ophthalmic devices and technologies for the treatment of retinal disorders. The company offers implantable miniature telescope, an implantable medical device t …
  • University of Rochester-製薬・医療分野:企業M&A・提携分析
    Summary University of Rochester (UOR) is an educational university that offers research and development services. The university performs research in the areas of humanities, engineering medical education, medicine, geology, optics, economics, political theory, human behavior, and social and natural …
  • Exchange Income Corporation:企業の戦略・SWOT・財務分析
    Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report Summary Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Eddie Stobart Logistics Plc:企業の戦略・SWOT・財務分析
    Eddie Stobart Logistics Plc - Strategy, SWOT and Corporate Finance Report Summary Eddie Stobart Logistics Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NuScale Power LLC:企業の戦略的SWOT分析
    NuScale Power LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Regal Entertainment Group:企業の戦略・SWOT・財務情報
    Regal Entertainment Group - Strategy, SWOT and Corporate Finance Report Summary Regal Entertainment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆